Abstract:BACKGROUND:Randomized controlled trials are considered the gold standard for evaluating experimental treatments but often require large sample sizes. Single-arm trials require smaller sample sizes but are subject to bias when using historical control data for comparative inferences. This article presents a Bayesian adaptive synthetic-control design that exploits historical control data to create a hybrid of a single-arm trial and a randomized controlled trial.METHODS:The Bayesian adaptive synthetic control design has two stages. In stage 1, a prespecified number of patients are enrolled in a single arm given the experimental treatment. Based on the stage 1 data, applying propensity score matching and Bayesian posterior prediction methods, the usefulness of the historical control data for identifying a pseudo sample of matched synthetic-control patients for making comparative inferences is evaluated. If a sufficient number of synthetic controls can be identified, the single-arm trial is continued. If not, the trial is switched to a randomized controlled trial. The performance of The Bayesian adaptive synthetic control design is evaluated by computer simulation.RESULTS:The Bayesian adaptive synthetic control design achieves power and unbiasedness similar to a randomized controlled trial but on average requires a much smaller sample size, provided that the historical control data patients are sufficiently comparable to the trial patients so that a good number of matched controls can be identified in the historical control data. Compared to a single-arm trial, The Bayesian adaptive synthetic control design yields much higher power and much smaller bias.CONCLUSION:The Bayesian adaptive synthetic-control design provides a useful tool for exploiting historical control data to improve the efficiency of single-arm phase II clinical trials, while addressing the problem of bias when comparing trial results to historical control data. The proposed design achieves power similar to a randomized controlled trial but may require a substantially smaller sample size.

BAYESIAN HIERARCHICAL RANDOM-EFFECTS META-ANALYSIS AND DESIGN OF PHASE I CLINICAL TRIALS

Phase I Trial Design for Drug Combinations with Bayesian Model Averaging.

Random-effects meta-analysis of phase I dose-finding studies using stochastic process priors

Bayesian hybrid dose-finding design in phase I oncology clinical trials.

BASIC: A Bayesian Adaptive Synthetic-Control Design for Phase II Clinical Trials.

Incorporating Historical Information to Improve Phase I Clinical Trials

Bayesian phase I/II adaptively randomized oncology trials with combined drugs

Bayesian Dose Finding by Jointly Modelling Toxicity and Efficacy As Time-To-Event Outcomes

Bayesian Phase II Adaptive Randomization by Jointly Modeling Time-to-event Efficacy and Binary Toxicity

Bayesian Optimal Phase II Design for Randomized Clinical Trials

A Bayesian phase I/II platform design for co-developing drug combination therapies for multiple indications

A Three-Stage Bayesian Adaptive Phase I/II Design and Simulation Studies.

Comparative Review of Novel Model‐assisted Designs for Phase I Clinical Trials

Comparative review of novel model-assisted designs for phase I clinical trials.

An Adaptive Trial Design to Optimize Dose-Schedule Regimes with Delayed Outcomes

A Bayesian Phase I/II Trial Design for Immunotherapy

A straightforward meta-analysis approach for oncology phase I dose-finding studies

A Bayesian Dose Finding Design for Oncology Clinical Trials of Combinational Biological Agents

A Bayesian Platform Trial Design to Simultaneously Evaluate Multiple Drugs in Multiple Indications with Mixed Endpoints.

BOIN12: Bayesian Optimal Interval Phase I/II Trial Design for Utility-Based Dose Finding in Immunotherapy and Targeted Therapies.

Bayesian Optimal Designs for Multi-Arm Multi-Stage Phase II Randomized Clinical Trials with Multiple Endpoints